ERBB2 and breast cancer: The EUSOMA international network of European breast centers also reported data on the distribution of BC subtypes among patients diagnosed between 2016–2021: 4.2%, 76.7%, 8.9%, and 10.1% of BC cases were as HER2+/HR–, HER2–/HR+, TNBC, and HER+/HR+ (22).